Biolog-id LLC Expands Partnership with Hoxworth Blood Center to Further Enhance Safety and Efficiency in the Management of Blood Products Across its Enterprise
Biolog-id LLC, a developer of end-to-end blood safety solutions and a leader in connected health solutions, announced today that it’s expanding its partnership with University of Cincinnati’s Hoxworth Blood Center to include the management of Red Blood Cell Concentrates, the most commonly requested blood product, in its cutting-edge technology ecosystem across its enterprise.
The expanded partnership, aimed at improving the lives of patients requiring transfusions, leverages Biolog-id patented technology within Hoxworth facilities. The technology, Biolog-Transfusion®, tracks blood products throughout the supply chain, providing real-time visibility into inventory across locations, and collecting data, allowing for comprehensive analysis. This is the first expansion following the appointment of Troy Hilsenroth to CEO of Biolog-id LLC.
“I am thrilled to be expanding our partnership with Hoxworth Blood Center, a trusted organization within the industry, as we expand and grow Biolog-id’s North American presence,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “With Hoxworth, we are committed to helping them achieve their vision by driving operational value and increasing clinical quality through our differentiated platform.”
Hoxworth Blood Center collects, tests, processes and distributes lifesaving blood to 31 hospitals and medical centers in Ohio, Kentucky and Indiana. The blood management ecosystem implemented at Hoxworth allows for the seamless addition of Red Blood Cells with a significant reduction of workload associated with the daily management of inventory and supports better data-driven decisions around the fulfilment of requests from the different hospitals.
"Our partnership with Biolog-id furthers our commitment to embracing innovative technologies to provide a reliable, safe supply of high value blood products to our patients,” said Jose A. Cancetas, Director of Hoxworth Blood Center. "The implementation of Biolog-id’s platform greatly improves the management and distribution of Platelet Concentrates and Red Blood Cell Concentrates as we look to maximize patient outcomes. We are excited for the expansion of our partnership to implement its innovative solutions across our enterprise.”
Biolog-id will be launching an additional pilot program in North America in Q4 2019 focused on the installation of its technology across another major healthcare network.
About Biolog-id
Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has over 100 employees worldwide. Biolog-id is owned by its founder, managers and the Xerys Funds.
Company URL: www.biolog-id.com
About Hoxworth Blood Center
Hoxworth Blood Center, University of Cincinnati was founded in 1938 and serves 31 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky and Southeastern Indiana. Annually, Hoxworth collects more than 80,000 units of blood from local donors to help save the lives of patients in area hospitals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005037/en/
Contact information
Sothea Shreck, 212.601.3392, Sothea.Shreck@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Investment of NXP in Kalray3.4.2020 00:52:00 EEST | Press release
Kalray (Euronext Growth Paris : ALKAL – the “Company”), a pioneer in processors for new intelligent systems, today announces a strategic investment from NXP Semiconductors N.V. (NASDAQ: NXPI) for €8 million (approximately US$9 million), to enable the companies to develop together safe, reliable and scalable solutions for autonomous driving, combining NXP Automotive solutions and Kalray MPPA® (Massively Parallel Processor Array) Intelligent Processors. The investment will be carried out through the reserved issuance to NXP BV, a company of the NXP Group, of 503,461 ordinary shares without pre-emptive rights for the existing shareholders of the Company. Upon settlement-delivery of the new shares, the NXP Group will hold ca. 9.95% of Kalray’s share capital and voting rights. The settlement-delivery of the new shares is scheduled for April 7, 2020 and their admission to the Euronext Growth Paris multilateral trading system is scheduled for April 8, 2020. STRATEGIC NATURE OF THE TRANSACTION
Kalray: Information About Covid-193.4.2020 00:05:00 EEST | Press release
Kalray (Paris:ALKAL) (Euronext Growth Paris : ALKAL), a pioneer in processors for new intelligent systems, is sharing the status on its activity and the continuation of its activity following the various health measures taken by the French government. The impact of Covid-19 epidemic on Kalray’s research and development activity, which is not too dependent on its suppliers, is expected to be limited and Kalray is hopeful it will be able to stick to its development roadmap. The development teams are fully operational thanks to telework, which was put in place as soon as the containment was announced in France on Monday March 16. The company does not use technical unemployment to date. However, the global health situation related to the Covid-19 epidemic and the containment measures implemented in many countries are likely to slow down business cycles, which could delay the deployment of some of company’s projects. At this stage, Kalray is currently assessing all the impacts of this crisi
VDX.tv Launches Global Digital Video PSA Initiative to Inform the Public About COVID-192.4.2020 17:00:00 EEST | Press release
VDX.tv, a global advertising technology company transforming the way brands connect with relevant audiences, today launched a digital video Public Service Announcement (PSA) initiative to help drive awareness around COVID-19 and better help global communities cope with the spread of the virus. The campaign will enable corporations, brands, publishers, marketers, and celebrities to work together to help combat this spread. The initiative recognizes that this virus has and continues to impact communities globally. VDX.tv’s video ads will be translated into several languages to reach people across all regions. Additionally, VDX.tv will use its platform’s full capabilities to customize messaging in each city and provide the most relevant information. “During this unprecedented situation, we’re determined to act and help do what we do best: connect with audiences through compelling video messaging and formats,” said Dilip DaSilva, CEO, VDX.tv. “Video is the best format for brands to communi
Shareholders Approve All AGM Resolutions and SES Board Elects Frank Esser as Chairperson2.4.2020 16:14:00 EEST | Press release
SES S.A. held its Annual General Meeting (AGM) today in Betzdorf, Luxembourg, in which all resolutions were approved by shareholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005503/en/ Shareholders Approve All AGM Resolutions and SES Board Elects Frank Esser as Chairperson (Photo: Business Wire) The meeting was held based on the rules set out in the Grand Ducal Regulation of 20 March 2020 with shareholders participating remotely by appointing SES designated proxyholders to represent them at the meeting and to carry out their voting instructions given ahead of the meeting. Compliance with voting instructions was verified by the bureau of the AGM. The approved resolutions included the company's 2019 financial accounts and the proposed dividend of EUR 0.40 per A-share which will be paid to shareholders on 23 April 2020. Accordingly, SES’s 2019 Annual Report has been published and is available to download at http://
New Visualizations in Airship Journeys Offer Breakthrough Simplicity to Perfect Cross-Channel Customer Experiences2.4.2020 16:00:00 EEST | Press release
Today, customer engagement company Airship revealed new Airship Journeys visualizations that make managing in-the-moment cross-channel customer experiences dramatically simpler and more effective for marketers. Now, for the first time, marketers can quickly zero in on underperforming campaigns with high-level views of performance and journey relationships and — in a few clicks — modify messages to improve performance or connect journeys to advance other marketing goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005186/en/ New visualizations in Airship Journeys condense sprawling branches of today’s journey tools into single cards that offer at-a-glance views of goal-based performance, enabling marketers to evaluate journey relationships and connect new ones to advance other goals. (Graphic: Business Wire) Airship Journeys simplifies all aspects of cross-channel customer engagement. Journey setup is guided and base
Largest Statistically Significant Study by 6,200 Multi-Country Physicians on COVID-19 Uncovers Treatment Patterns and Puts Pandemic in Context2.4.2020 16:00:00 EEST | Press release
Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, ethical choices, effectiveness of government responses, and much more. Multiple study waves including a deeper dive into treatments will be conducted over the next several weeks. To view results and countries visit sermo.com. Key findings; Sermo Real Time Barometer *: Treatments & Efficacy The three most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom